Genetic variants showed uneven links with chemotherapy side effects in gynecological cancers
A systematic review found potential associations with adverse reactions to carboplatin and paclitaxel, but inconsistent results and study differences limit their clinical interpretation.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Some genetic variants appeared to be associated with adverse reactions during carboplatin-paclitaxel treatment, including low blood-cell counts and peripheral sensory neuropathy. Other variants produced inconsistent findings. The review identifies possible treatment biomarkers, but the abstract does not establish that genetic testing can reliably predict side effects or improve chemotherapy decisions for individual patients.
Substantial differences among studies prevented meta-analysis, and representation was concentrated in Asian and European populations. The abstract does not provide association sizes, confidence intervals or variant-specific follow-up, limiting assessment of clinical usefulness and applicability.
What the review examined
The researchers searched for genetic variants associated with clinical outcomes during this chemotherapy combination. The main results highlighted adverse reactions involving neutrophils, platelets and peripheral sensory nerves, alongside variants for which the evidence did not agree.
Why these remain candidate markers
An association between a variant and an adverse reaction does not establish a dependable prediction for a particular patient. The authors call for broader analyses and more inclusive study groups to clarify how widely the findings apply.
The original publication
Genetic Polymorphisms as Treatment Biomarkers for Gynecological Malignancies Treated With Carboplatin and Paclitaxel: A Systematic Review.
Torso NG, Matos YG, Fidelis GFS et al.
Clin Ther · 2025
- PubMed ID
- 40784820
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.